PTGX – Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc.PTGX
$43.77Name : Protagonist Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,712,952,064.00
EPSttm : 0.78
Protagonist Therapeutics, Inc.
$43.77
1.13%$0.5Float Short %
10.47
Margin Of Safety %
35
Put/Call OI Ratio
0.68
EPS Next Q Diff
-0.34
EPS Last/This Y
-5.88
EPS This/Next Y
0.28
Price
43.73
Target Price
68.36
Analyst Recom
1.18
Performance Q
16.97
Relative Volume
0.66
Beta
2.23
Ticker: PTGX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | PTGX | 44.99 | 0.64 | 0.78 | 20443 |
| 2025-04-15 | PTGX | 46.96 | 0.66 | 0.11 | 20581 |
| 2025-04-16 | PTGX | 45.8 | 0.70 | 0.07 | 19790 |
| 2025-04-17 | PTGX | 46.32 | 0.67 | 0.08 | 19710 |
| 2025-04-18 | PTGX | 46.28 | 0.67 | 0.08 | 19710 |
| 2025-04-21 | PTGX | 45.85 | 0.72 | 0.67 | 8228 |
| 2025-04-22 | PTGX | 45.83 | 0.73 | 0.00 | 8329 |
| 2025-04-23 | PTGX | 46.17 | 0.72 | 0.07 | 8348 |
| 2025-04-24 | PTGX | 44.86 | 0.72 | 1.13 | 8353 |
| 2025-04-25 | PTGX | 44.49 | 0.72526793075021 | 0 | 8371 |
| 2025-04-28 | PTGX | 44.39 | 0.72258726899384 | 6 | 8389 |
| 2025-04-29 | PTGX | 45.58 | 0.72 | 0.00 | 8401 |
| 2025-04-30 | PTGX | 46.06 | 0.72 | 999.99 | 8433 |
| 2025-05-01 | PTGX | 45 | 0.72 | 0.11 | 8434 |
| 2025-05-02 | PTGX | 45.55 | 0.70 | 1.89 | 8560 |
| 2025-05-05 | PTGX | 44.26 | 0.71 | 1.00 | 8589 |
| 2025-05-06 | PTGX | 42 | 0.71 | 0.27 | 8595 |
| 2025-05-07 | PTGX | 43.08 | 0.71 | 0.00 | 8630 |
| 2025-05-08 | PTGX | 43.95 | 0.71 | 0.24 | 8629 |
| 2025-05-09 | PTGX | 42.98 | 0.70 | 0.00 | 8765 |
| 2025-05-12 | PTGX | 45.32 | 0.70 | 0.54 | 8770 |
| 2025-05-13 | PTGX | 44.47 | 0.71 | 0.01 | 8778 |
| 2025-05-14 | PTGX | 43.75 | 0.68 | 0.09 | 9001 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | PTGX | 45.03 | -96.6 | - | -1.23 |
| 2025-04-15 | PTGX | 46.95 | -96.6 | - | -1.23 |
| 2025-04-16 | PTGX | 45.87 | -96.6 | - | -1.23 |
| 2025-04-17 | PTGX | 46.28 | -96.6 | - | -1.23 |
| 2025-04-18 | PTGX | 46.28 | -96.6 | - | -1.23 |
| 2025-04-21 | PTGX | 45.79 | -96.6 | - | -1.23 |
| 2025-04-22 | PTGX | 45.85 | -96.6 | - | -1.23 |
| 2025-04-23 | PTGX | 46.16 | -96.6 | - | -1.23 |
| 2025-04-24 | PTGX | 44.87 | -96.6 | - | -1.23 |
| 2025-04-25 | PTGX | 44.49 | -96.6 | - | -1.23 |
| 2025-04-28 | PTGX | 44.39 | -96.6 | - | -1.23 |
| 2025-04-29 | PTGX | 45.62 | -96.6 | - | -1.23 |
| 2025-04-30 | PTGX | 45.82 | -96.6 | - | -1.23 |
| 2025-05-01 | PTGX | 44.99 | -96.6 | - | -1.23 |
| 2025-05-02 | PTGX | 45.51 | -96.6 | - | -1.23 |
| 2025-05-05 | PTGX | 44.28 | -96.6 | - | -1.23 |
| 2025-05-06 | PTGX | 42.01 | -96.6 | - | -1.23 |
| 2025-05-07 | PTGX | 43.09 | -96.6 | - | -1.23 |
| 2025-05-08 | PTGX | 43.94 | -5.8 | - | -1.22 |
| 2025-05-09 | PTGX | 42.97 | -0.9 | - | -1.57 |
| 2025-05-12 | PTGX | 45.27 | -0.9 | - | -1.57 |
| 2025-05-13 | PTGX | 44.27 | -0.9 | - | -1.41 |
| 2025-05-14 | PTGX | 43.73 | -0.9 | - | -1.41 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | PTGX | -8.39 | 3.67 | 8.13 |
| 2025-04-15 | PTGX | -8.39 | 3.67 | 8.13 |
| 2025-04-16 | PTGX | -8.39 | 3.67 | 8.13 |
| 2025-04-17 | PTGX | -8.39 | 3.67 | 8.13 |
| 2025-04-18 | PTGX | -8.39 | 3.67 | 8.13 |
| 2025-04-21 | PTGX | -8.39 | 6.59 | 8.13 |
| 2025-04-22 | PTGX | -8.39 | 6.59 | 8.13 |
| 2025-04-23 | PTGX | -8.43 | 6.59 | 8.13 |
| 2025-04-24 | PTGX | -8.43 | 6.59 | 8.13 |
| 2025-04-25 | PTGX | -8.43 | 6.59 | 8.13 |
| 2025-04-28 | PTGX | -8.43 | 6.63 | 9.62 |
| 2025-04-29 | PTGX | -8.43 | 6.63 | 9.62 |
| 2025-04-30 | PTGX | -8.43 | 6.63 | 9.62 |
| 2025-05-01 | PTGX | -8.43 | 6.63 | 9.62 |
| 2025-05-02 | PTGX | -8.43 | 6.63 | 9.62 |
| 2025-05-05 | PTGX | -8.43 | 5.86 | 9.62 |
| 2025-05-06 | PTGX | -8.43 | 5.86 | 9.62 |
| 2025-05-07 | PTGX | -8.40 | 5.86 | 9.62 |
| 2025-05-08 | PTGX | -8.40 | 5.86 | 9.62 |
| 2025-05-09 | PTGX | -8.33 | 5.86 | 9.53 |
| 2025-05-12 | PTGX | -8.33 | 1.54 | 10.47 |
| 2025-05-13 | PTGX | -8.33 | 1.54 | 10.47 |
| 2025-05-14 | PTGX | -8.33 | 1.54 | 10.47 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.19
Avg. EPS Est. Current Quarter
-0.5
Avg. EPS Est. Next Quarter
-0.53
Insider Transactions
-8.33
Institutional Transactions
1.54
Beta
2.23
Average Sales Estimate Current Quarter
7
Average Sales Estimate Next Quarter
7
Fair Value
59.09
Quality Score
58
Growth Score
62
Sentiment Score
72
Actual DrawDown %
27.8
Max Drawdown 5-Year %
-85.8
Target Price
68.36
P/E
57.54
Forward P/E
PEG
P/S
13.06
P/B
3.93
P/Free Cash Flow
8.09
EPS
0.76
Average EPS Est. Cur. Y
-1.41
EPS Next Y. (Est.)
-1.14
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
27.04
Relative Volume
0.66
Return on Equity vs Sector %
-15.5
Return on Equity vs Industry %
1.3
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.19
EBIT Estimation
Protagonist Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 124
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading